Canadian Respiratory Journal / 2017 / Article / Tab 5

Research Article

Impaired Hemorheology in Exacerbations of COPD

Table 5

The RBC aggregation measurements of the groups.

Control group ( = 12) Newly diagnosed patient groupExacerbation group
( = 16)
Before treatment
( = 13)
After treatment
( = 13)

AMP (au)25.0 ± 2.9125.1 ± 3.9024.65 ± 3.180.0020.002
AI (%)68.15 ± 5.9072.33 ± 6.1673.16 ± 8.170.00010.007
(sn)1.79 ± 0.551.45 ± 0.551.39 ± 0.680.0010.003

Values are expressed as means ± SD; AMP: amplitude of aggregation; AI: aggregation index; : aggregation half time. : difference between the control group, before treatment of newly diagnosed COPD, and the exacerbation group; : difference between the control group, after treatment of newly diagnosed COPD, and the exacerbation group; < 0.05: difference from control, < 0.05: difference from before treatment of COPD, and < 0.05: difference from after treatment of COPD.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.